CVRx Prepares to Share Its Q3 2025 Insights
CVRx, Inc. (NASDAQ: CVRX), a leader in the medical device industry, is gearing up to announce its financial and operational results for the third quarter of 2025. The exciting announcement is set to occur after the market closes on Wednesday, November 5, 2025. This provides a timely opportunity for investors and stakeholders to gain insight into the company's performance as well as future direction.
Anticipating the Upcoming Conference Call
Following the release of the financial results, CVRx will host a conference call at 4:30 PM Eastern Time on the same day. This conference call is a platform for the company to delve into the details of their results and answer any pressing questions that may arise from investors and analysts alike.
How to Join the Conference Call
To engage in this informative session, interested participants can join via telephone. The dial-in number for U.S. callers is 1-877-704-4453, and for international attendees, it's 1-201-389-0920. It's recommended to connect approximately ten minutes before the call starts to ensure you're ready for the insightful discussions ahead.
Insight into CVRx's Mission and Innovations
CVRx is dedicated to innovating solutions specifically in the realm of neuromodulation for patients dealing with cardiovascular diseases. Its flagship product, Barostim™, is the first medical technology approved by the FDA that employs neuromodulation for enhancing the lives of those suffering from heart failure. This groundbreaking implantable device sends electrical impulses to baroreceptors in the carotid artery, aiming to restore equilibrium within the autonomic nervous system, which is often disrupted in heart failure patients.
The Transformative Impact of Barostim
Barostim has not only received FDA Breakthrough Device designation but has also earned FDA approval for its use in patients with heart failure in the U.S. Beyond North America, Barostim holds certification under the EU Medical Device Regulation (MDR) and has the CE Mark for treatment in the European Economic Area, addressing both heart failure and resistant hypertension. As such, this device represents a significant advancement in the treatment options available to patients and underlines CVRx's commitment to improving patient outcomes.
Investors and Media Contacts for Further Insights
For those looking to dig deeper into CVRx’s strategies and product offerings, investor inquiries can be directed to Mark Klausner or Mike Vallie at ICR Healthcare by calling 443-213-0501. Additionally, media professionals seeking insights or further information can reach Emily Meyers at CVRx by calling 763-416-2853 for an in-depth discussion.
Frequently Asked Questions
What financial results will CVRx report on November 5, 2025?
CVRx is set to announce its financial performance and operations for the third quarter of 2025.
What is Barostim and how does it work?
Barostim is an implantable device that utilizes neuromodulation to help patients with cardiovascular diseases by sending electrical pulses to baroreceptors.
How can I listen to the conference call?
Interested listeners can join the conference call by dialing the appropriate number based on their location, ten minutes prior to the start time.
What designations has Barostim received from regulatory bodies?
Barostim has received FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients.
How can I contact CVRx for investor or media inquiries?
For investor inquiries, contact Mark Klausner or Mike Vallie, and for media inquiries, reach out to Emily Meyers for further assistance.
